Clinical trials
Pneumonia trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 3 |
| 2016 | 3 |
| 2017 | 4 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Unknown status | 5 |
| Not yet recruiting | 3 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Taichung Veterans General Hospital | 4 |
| National Cheng-Kung University Hospital | 3 |
| National Taiwan University Hospital | 3 |
| Chang Gung Memorial Hospital | 2 |
| Chung Shan Medical University | 2 |
| Pfizer | 2 |
| TaiGen Biotechnology Co., Ltd. | 2 |
| Taipei Medical University WanFang Hospital | 2 |
| Aridis Pharmaceuticals, Inc. | 1 |
| Mackay Memorial Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pneumonia | 32 |
| COVID-19 | 3 |
| Community-Acquired Pneumonia | 3 |
| Asthma | 2 |
| Coronavirus Infections | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Infections | 2 |
| Lung Diseases | 2 |
| Pleural Effusion | 2 |
| Pneumonia, Bacterial | 2 |
Trials
Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.